



Announcement Summary

Entity name

CLARITY PHARMACEUTICALS LTD

Date of this announcement

Tuesday December 02, 2025

The +securities the subject of this notification are:

+Other securities issued under an +employee incentive scheme that are not intended to be quoted on ASX

Total number of +securities to be issued/transferred

| ASX +security code | Security description | Total number of +securities to be issued/transferred | Issue date |
|--------------------|---|--|------------|
| CU6AAM | OPTION EXPIRING VARIOUS DATES EX VARIOUS PRICES | 12,797 | 10/11/2025 |
| CU6AAM | OPTION EXPIRING VARIOUS DATES EX VARIOUS PRICES | 89,892 | 17/11/2025 |
| CU6AAM | OPTION EXPIRING VARIOUS DATES EX VARIOUS PRICES | 2,262,087 | 25/11/2025 |

Refer to next page for full details of the announcement



Part 1 - Entity and announcement details

1.1 Name of entity

CLARITY PHARMACEUTICALS LTD

We (the entity named above) give notice of the issue, conversion or payment up of the following unquoted +securities.

1.2 Registered number type

ACN

Registration number

143005341

1.3 ASX issuer code

CU6

1.4 The announcement is

New announcement

1.5 Date of this announcement

2/12/2025



Part 2 - Issue details

2.1 The +securities the subject of this notification are:

+Other securities issued under an +employee incentive scheme that are not intended to be quoted on ASX

2.2a This notification is given in relation to an issue of +securities in a class which is not quoted on ASX and which:

has an existing ASX security code ("existing class")



Part 3B - number and type of +securities the subject of this notification (existing class) where issue has not previously been notified to ASX in an Appendix 3B

ASX +security code and description

CU6AAM : OPTION EXPIRING VARIOUS DATES EX VARIOUS PRICES

Date the +securities the subject of this notification were issued

10/11/2025

Will these +securities rank equally in all respects from their issue date with the existing issued +securities in that class

Yes

Were any of the +securities issued to +key management personnel (KMP) or an +associate?

No

Please provide a URL link for a document lodged with ASX detailing the terms of the +employee incentive scheme or a summary of the terms

<https://www.claritypharmaceuticals.com/wp-content/uploads/2023/05/Clarity-Pharmaceuticals-Ltd-Prospectus.pdf>

Any other information the entity wishes to provide about the +securities the subject of this notification

Options vest as follows, subject to the option holder remaining employed by the company:

25% on 10 November 2026

25% on 10 November 2027

50% on 10 November 2028

Issue details

Number of +securities

12,797

ASX +security code and description

CU6AAM : OPTION EXPIRING VARIOUS DATES EX VARIOUS PRICES

Date the +securities the subject of this notification were issued

17/11/2025

Will these +securities rank equally in all respects from their issue date with the existing issued +securities in that class

Yes

Were any of the +securities issued to +key management personnel (KMP) or an +associate?

No

Please provide a URL link for a document lodged with ASX detailing the terms of the +employee incentive scheme or a summary of the terms

<https://www.claritypharmaceuticals.com/wp-content/uploads/2023/05/Clarity-Pharmaceuticals-Ltd-Prospectus.pdf>

**Any other information the entity wishes to provide about the +securities the subject of this notification**

Options vest as follows, subject to the option holder remaining employed by the company:

25% on 17 November 2026

25% on 17 November 2027

50% on 17 November 2028

Issue details

Number of +securities

89,892

ASX +security code and description

CU6AAM : OPTION EXPIRING VARIOUS DATES EX VARIOUS PRICES

Date the +securities the subject of this notification were issued

25/11/2025

Will these +securities rank equally in all respects from their issue date with the existing issued +securities in that class

Yes

Were any of the +securities issued to +key management personnel (KMP) or an +associate?

Yes

Provide details of the KMP or +associates being issued +securities.

| Name of KMP | Name of registered holder | Number of +securities |
|-----------------|---------------------------|-----------------------|
| Alan Taylor | Alan Taylor | 517,916 |
| Michelle Parker | Michelle Parker | 209,904 |
| Colin Biggin | Colin Biggin | 199,909 |

Please provide a URL link for a document lodged with ASX detailing the terms of the +employee incentive scheme or a summary of the terms

<https://www.claritypharmaceuticals.com/wp-content/uploads/2023/05/Clarity-Pharmaceuticals-Ltd-Prospectus.pdf>

Any other information the entity wishes to provide about the +securities the subject of this notification

Vesting of the options is subject to continuous employment by the Company during the Performance Period (1 July 2025 - 30 June 2028 inclusive) and the achievement of specific performance hurdles as outlined in the 2025 Notice of Annual General Meeting. The issue of the options was approved by shareholders at the 2025 Annual General Meeting.



Issue details

Number of +securities

927,729

ASX +security code and description

CU6AAM : OPTION EXPIRING VARIOUS DATES EX VARIOUS PRICES

Date the +securities the subject of this notification were issued

25/11/2025

Will these +securities rank equally in all respects from their issue date with the existing issued +securities in that class

Yes

Were any of the +securities issued to +key management personnel (KMP) or an +associate?

Yes

Provide details of the KMP or +associates being issued +securities.

| Name of KMP | Name of registered holder | Number of +securities |
|-----------------|---------------------------|-----------------------|
| Alan Taylor | Alan Taylor | 744,922 |
| Michelle Parker | Michelle Parker | 301,906 |
| Colin Biggin | Colin Biggin | 287,530 |

Please provide a URL link for a document lodged with ASX detailing the terms of the +employee incentive scheme or a summary of the terms<https://www.claritypharmaceuticals.com/wp-content/uploads/2023/05/Clarity-Pharmaceuticals-Ltd-Prospectus.pdf>**Any other information the entity wishes to provide about the +securities the subject of this notification**

Vesting of the options is subject to the achievement of Total Shareholder Return (TSR) Performance Criteria and continuous employment during the Performance Period (1 July 2025 - 30 June 2028 inclusive) as outlined in the 2025 Notice of Annual General Meeting. The issue of the options was approved by shareholders at the 2025 Annual General Meeting.

Issue details

Number of +securities

1,334,358

Part 4 - +Securities on issue

Following the issue, conversion or payment up of the +securities the subject of this notification, the +securities of the entity will comprise:

The figures in parts 4.1 and 4.2 below are automatically generated and may not reflect the entity's current issued capital if other Appendix 2A, Appendix 3G or Appendix 3H forms are currently with ASX for processing.

4.1 Quoted +securities (Total number of each +class of +securities issued and quoted on ASX)

| ASX +security code and description | Total number of +securities on issue |
|---|---|
| CU6 : ORDINARY FULLY PAID | 372,030,071 |

4.2 Unquoted +securities (Total number of each +class of +securities issued but not quoted on ASX)

| ASX +security code and description | Total number of +securities on issue |
|--|---|
| CU6AAM : OPTION EXPIRING VARIOUS DATES EX VARIOUS PRICES | 20,548,867 |
| CU6AN : OPTION EXPIRING 10-MAY-2026 EX \$0.94 | 1,175,000 |



Part 5 - Other Listing Rule requirements

5.1 Were the +securities issued under an exception in Listing Rule 7.2 and therefore the issue did not need any security holder approval under Listing Rule 7.1?

Yes

5.1a Select the number of the applicable exception in Listing Rule 7.2

13